SCHEMBL6417244

SCHEMBL6417244

Clc1ccc(Nc2nc3nonc3nc2N/N=C\c2ccc(-c3ccccc3)o2)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BIRC5 O15392 1/20 0.53
MAPT P10636 13/20 0.43
MEN1 O00255 6/20 0.43
KMT2A Q03164 6/20 0.43
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
KDM4E B2RXH2 7/20 0.43
GAA P10253 5/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 4/20 0.43
NPSR1 Q6W5P4 3/20 0.43
HSP90AA1 P07900 1/20 0.43
ALOX12 P18054 1/20 0.43
HTT P42858 2/20 0.40
RCE1 Q9Y256 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
TP53 P04637 2/20 0.39
CCR2 P41597 1/20 0.39
CCR5 P51681 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6417246 1.00 BIRC5 (0.53) BIRC5MAPTMEN1KMT2ANPC1
SCHEMBL6414677 0.92 BIRC5 (0.51) BIRC5MAPTMEN1KMT2ANPC1
SCHEMBL6414682 0.92 BIRC5 (0.51) BIRC5MAPTMEN1KMT2ANPC1
SCHEMBL6414740 0.89 BIRC5 (0.57) BIRC5MAPTMEN1KMT2ANPC1
SCHEMBL6414735 0.89 BIRC5 (0.57) BIRC5MAPTMEN1KMT2ANPC1
SCHEMBL6419739 0.89 BIRC5 (0.69) BIRC5MAPTMEN1KMT2ANPC1
SCHEMBL6419742 0.89 BIRC5 (0.69) BIRC5MAPTMEN1KMT2ANPC1
SCHEMBL6418018 0.89 BIRC5 (0.55) BIRC5MAPTMEN1KMT2ANPC1
SCHEMBL6418022 0.89 BIRC5 (0.55) BIRC5MAPTMEN1KMT2ANPC1
SCHEMBL6420773 0.88 BIRC5 (0.57) BIRC5MAPTMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 BIRC5 2525/4885MAPT 4420/4885MEN1 4392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.